Biomarker‐driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral S rc inhibitor, in previously treated pancreatic cancer-Reference-Cited by-同舟云学术

Biomarker‐driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral S rc inhibitor, in previously treated pancreatic cancer

Published:2012-08-16 Issue:2 Volume:1 Page:207-217
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Arcaroli John¹,Quackenbush Kevin¹,Dasari Arvind²,Powell Rebecca¹,McManus Martine¹,Tan Aik‐Choon¹,Foster Nathan R.³,Picus Joel⁴,Wright John⁵,Nallapareddy Sujatha¹,Erlichman Charles³,Hidalgo Manuel⁶,Messersmith Wells A.¹

Affiliation:

1. University of Colorado Cancer Center Denver Colorado

2. University of Texas MD Anderson Cancer Center Houston Texas

3. Mayo Clinic Cancer Center Rochester Minnesota

4. Washington University School of Medicine St. Louis Missouri

5. Cancer Therapy Evaluation Program Bethesda Maryland

6. Centro Nacional de Investigaciones Oncológicas Madrid Spain

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link